LEADER 00000cam  2200733Ka 4500 
001    ocm55664162  
003    OCoLC 
005    20190811034344.6 
006    m     o  d         
007    cr cn||||||||| 
008    040211s2003    sz     go     000 0 eng d 
019    54063535|a191039474|a488487281|a614539793|a647288505
       |a722204078|a728011383|a827878575|a961650365|a962561733
       |a994397383 
020    9240681531 
020    9789240681538 
020    0585492727 
020    9780585492728 
020    9789241209151 
020    9241209151 
020    |z9241209151 
035    (OCoLC)55664162|z(OCoLC)54063535|z(OCoLC)191039474
       |z(OCoLC)488487281|z(OCoLC)614539793|z(OCoLC)647288505
       |z(OCoLC)722204078|z(OCoLC)728011383|z(OCoLC)827878575
       |z(OCoLC)961650365|z(OCoLC)962561733|z(OCoLC)994397383 
040    CSL|beng|epn|cCSL|dOCLCQ|dYDXCP|dOCLCQ|dDKDLA|dADU|dE7B
       |dMHW|dFVL|dOCLCQ|dMERUC|dEBLCP|dOCLCO|dOCLCQ|dVLB|dOCLCF
       |dOCLCQ|dCUS|dOCLCQ|dN$T|dZMC|dOCLCQ|dAZK|dCOCUF|dMOR|dZ5A
       |dOCLCO|dPIFBR|dZCU|dXFH|dOCLCO|dOCLCQ|dOCLCO|dOCLCA|dU3W
       |dOCLCA|dSTF|dWRM|dNRAMU|dICG|dVT2|dOCLCQ|dCUY|dOCLCO
       |dOCLCA|dTKN|dDKC|dAU@|dOCLCQ|dOCLCO|dM8D|dUMK 
049    STJJ 
050  4 HV4998|b.W46 2003eb 
070    449.9|bW892T no. 915 
072  7 SEL|x026000|2bisacsh 
072  7 PSY|x038000|2bisacsh 
082 04 362.29 
245 00 WHO Expert Committee on Drug Dependence :|bthirty-third 
       report. 
264  1 Geneva :|bWorld Health Organization,|c2003. 
300    1 online resource (31 pages). 
336    text|btxt|2rdacontent 
337    computer|bc|2rdamedia 
338    online resource|bcr|2rdacarrier 
347    data file|2rda 
490 1  WHO technical report series ;|v915 
505 0  1. Introduction; 2. Scheduling criteria; 3. Critical 
       review of psychoactive substances; 4. Pre-review of 
       psychoactive substances; 5. Terminology used in reporting 
       abuse-related adverse drug reactions; 6. Other matters; 
       Acknowledgements; References; Annex Terminology used in 
       reporting abuse-related adverse drug reactions; 
       References. 
520    This report presents the recommendations of a WHO Expert 
       Committee responsible for reviewing information on 
       dependence-producing drugs to assess the need for their 
       international control. The first part of the report 
       contains a summary of the Committee's evaluations of seven
       substances (dronabinol, oripavine, buprenorphine, 
       butorphanol, ketamine, khat and zopiclone). The report 
       also discusses the substances that were pre-reviewed 
       (gamma-hydroxybutyric acid and tramadol) and recommended 
       gamma-hydroxybutyric acid for critical review at a future 
       meeting. Two substances (gamma-butyrolactone and 1,4-
       butanediol) were identified for future pre-review). 
546    English. 
588 0  Print version record. 
590    EBSCOhost|bSocINDEX with Full Text 
650  0 Substance abuse. 
650  0 Drug abuse. 
650  0 Designer drugs. 
650  0 Stereoisomers. 
650  0 Ephedrine. 
650  2 Psychotropic Drugs. 
650  2 Substance-Related Disorders. 
650  2 Drug and Narcotic Control. 
650  2 Catha. 
650  7 SELF-HELP|xSubstance Abuse & Addictions|xGeneral.|2bisacsh
650  7 PSYCHOLOGY|xPsychopathology|xAddiction.|2bisacsh 
650  7 Designer drugs.|2fast|0(OCoLC)fst00891339 
650  7 Drug abuse.|2fast|0(OCoLC)fst00898480 
650  7 Ephedrine.|2fast|0(OCoLC)fst00913670 
650  7 Stereoisomers.|2fast|0(OCoLC)fst01133146 
650  7 Substance abuse.|2fast|0(OCoLC)fst01136767 
655  0 Electronic books. 
655  7 Electronic books.|2lcgft 
776 08 |iPrint version:|tWHO Expert Committee on Drug Dependence.
       |dGeneva : World Health Organization, ©2003|z9241209151
       |w(OCoLC)52313359 
830  0 Technical report series (World Health Organization) ;
       |v915. 
914    ocm55664162 
994    92|bSTJ